Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference

NCT00219167 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
February 28, 2006
Enrollment
355 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension